Tag: DESTINY-Gastric01
FDA Grants Priority Review for Trastuzumab deruxtecan in HER2 Positive Metastatic...
The U.S. Food and Drug Administration (FDA) has granted Priority Review for Trastuzumab deruxtecan (fam-trastuzumab deruxtecan-nxki; DS-1062; Enhertu®; Daiichi Sankyo and AstraZeneca) for the...
Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in...
In a statement earlier today, Daiichi Sankyo confirmed that it has submitted a supplemental New Drug Application (sNDA) to Japan’s Ministry of Health, Labour...
First Patient Dosed in Pivotal Phase II DESTINY-Gastric01 Study of DS-8201
A first patient has been enrolled in DESTINY-Gastric01 (NCT03329690), a pivotal phase II study in Japan and South Korea evaluating the safety and efficacy...
